New directions in the development of antidepressants: the interface of neurobiology and psychiatry.

New directions in the development of antidepressants: the interface of neurobiology and psychiatry. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

New directions in the development of antidepressants: the interface of neurobiology and psychiatry. Abstract Text:

There have been considerable advances in neurobiology in recent years that are providing new directions for the development of novel classes of antidepressants. For example, the finding that corticotropin-releasing factor (CRF) is hypersecreted in depressed patients and mediates certain symptoms of depression has led to the development of specific antagonists of the CRF(1) receptor. These are expected to prove highly effective for the treatment of mood and anxiety disorders. Another related avenue of research is based on evidence that cortisol is integral to the pathophysiology of major depression with psychotic features. One alternative for treating this subtype of affective disorder is, therefore, to block the action of glucocorticoids using a receptor antagonist such as mifepristone. These are just two of the many new directions that will likely lead to the development of antidepressants in the near future.

New directions in the development of antidepressants: the interface of neurobiology and psychiatry. Publishing Authors By Initials

For similar proteins: receptors, cytoplasmic and nuclear: receptors, steroid: receptors, glucocorticoid research abstracts see: proteins: receptors, cytoplasmic and nuclear: receptors, steroid: receptors, glucocorticoid research

PUBMED ID PMID:

MEDLINE DATE:

New directions in the development of antidepressants: the interface of neurobiology and psychiatry. Journal Published:

PUBLICATION TYPE: Review

Journal: Human psychopharmacology

VOLUME: 17 Suppl 1

Page Numbers: S13-6

Journal Abbreviation: Hum Psychopharmacol

ISSN: 0885-6222

DAY: 6

MONTH: Jun

YEAR: 2002

New directions in the development of antidepressants: the interface of neurobiology and psychiatry. Information

Number of References: 23

LANGUAGE: eng

NlmUniqueID: 8702539

New directions in the development of antidepressants: the interface of neurobiology and psychiatry. Keywords Mesh Terms:

KEYWORDS: Receptors, Glucocorticoid

MESH TERMS: metabolism

Chemical & Substance for Abstract: New directions in the development of antidepressants: the interface of neurobiology and psychiatry. Information

Substance Name: Corticotropin-Releasing Hormone

Registry Number: 9015-71-8

Grant and Affiliation Information for New directions in the development of antidepressants: the interface of neurobiology and psychiatry.

AFFILIATION: Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia 30322-4990, USA. cnemoro@emory.edu

Country: England

AGENCY: United States NIMH

GRANT: NIMH-42088

ACRONYM: MH

MEDLINETA: Hum Psychopharmacol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

New directions in the development of antidepressants: the interface of neurobiology and psychiatry Related Publications

• An interactive web-based method of outreach to college students at risk for suicide.
• CSF corticotropin releasing hormone, somatostatin, and thyrotropin releasing hormone in schizophrenia.
• Cuba II: A Land Stuck in Time.
• Cuba: a land stuck in time.
• Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy.
• Depression and endocrine disorders: focus on the thyroid and adrenal system.
• Depression, desperation, and suicidal ideation in college students: results from the American Foundation for Suicide Prevention College Screening Project at Emory University.
• Drug development for anxiety disorders: new roles for atypical antipsychotics.
• Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders.
• Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects.
• Emerging treatments for depression.
• Endogenous neurotensin is involved in estrous cycle related alterations in prepulse inhibition of the acoustic startle reflex in female rats.
• Fostering foster care outcomes: quality of intervention matters in overcoming early adversity.
• How are you?
• Involvement of neuropeptide systems in schizophrenia: human studies.
• Neuropeptides and Alzheimer's disease.
• Neurotensin: role in psychiatric and neurological diseases.
• New directions in the development of antidepressants: the interface of neurobiology and psychiatry.
• One brain, but different clinical disciplines: should psychiatry and neurology be United?
• Overview of the safety of citalopram.
• Sertraline and desmethylsertraline in human breast milk and nursing infants.
• Stress, menopause and vulnerability for psychiatric illness.
• The burden of severe depression: a review of diagnostic challenges and treatment alternatives.
• The dexamethasone/corticotropin-releasing factor test in men with major depression: role of childhood trauma.
• The interaction of serotonin transporter gene polymorphisms and early adverse life events on vulnerability for major depression.
• The neurobiology of bipolar disorder.
• The neurobiology of social anxiety disorder: the relevance of fear and anxiety.
• The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations.
• The role of patient advocacy in funding policy.
• Understanding the pathophysiology of postpartum depression: implications for the development of novel treatments.